TOXICITIES ASSOCIATED WITH CAR-T CELL THERAPIES CAR-T Cell Toxicity
Main Article Content
Keywords
Car-T; Toxicity, Infections, CRS, ICANS
Abstract
Chimeric antigen receptor (CAR) T-cells therapy has improved the outcomes of patients with relapsed/refractory B-cell lymphomas, B-cell acute lymphoblastic leukemia and multiple myeloma. However, CAR-T cell therapy is also associated with distinct toxicities that contribute to morbidity and mortality. A large number of studies now define the different toxicities associated with CAR-T cell therapy and have, in part, clarified their mechanisms. In particular, cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) are the two main acute toxicity events that occur after CAR-T cell infusion. Other CAR-T-related toxicities occur later after CAR-T cell infusion and include B-cell aplasia, hypogammaglobulinemia, infections and cytopenia. Infections represent the main cause of non-relapse death observed in patients undergoing CAR-T cell therapy. Second primary malignancies are rare and are mainly represented by myeloid malignancies.
Downloads
Download data is not yet available.
Abstract 11
PDF Downloads 5
HTML Downloads 0
References
References
1. Cordas dos Santos, D.; Tix, T.; Shouval, R.; Gafter-Gvili, A.; Alberge, J.B.; Scheffer Cliff, E.; Theurich, S.; Bargwelt-Baildon, M.; Ghobrial, I.M.; Subklewe, M.; et al. A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy. Nat Med 2024; 30: 2667-2678.
2. Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, Maus MV, Park JH, Mead E, Pavletic S, Go WY, Eldjerou L, Gardner RA, Frey N, Curran KJ, Peggs K, Pasquini M, DiPersio JF, van den Brink MRM, Komanduri KV, Grupp SA, Neelapu SS. ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. Biol Blood Marrow Transplant. 2019 Apr;25(4):625-638. doi: 10.1016/j.bbmt.2018.12.758. Epub 2018 Dec 25. PMID: 30592986.
3. Morris EC, Neelapu SS, Giavridis T, Sadelain M. Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy. Nat Rev Immunol 2022; 22: 85-96.
4. Giavridis T, van der Stegen SJG, Eyquem J, Hamieh M, Piersigilli A, Sadelain M.CAR T cell-induced cytokine release syndrome is mediated by macrophages and ablated by IL-1 blockade. Nat Med 2018; 24: 731-738.
5. Norelli M, Camisa B, Barbiera G, Falcone l, Purevdorj A, Genua M, Sanvito F, Ponzoni M, Doglioni C, Cristofori P. Monocyte derived IL-1 and IL-6 are differentially required for cytokine release syndrome and neurotoxicity due to CAR-T cells. Nat Med 2018; 24: 739-748.
6. Teachey DT, Lacey SF, Shaw PA, Malenhorst JJ, Maude SL, Frey N, Pequinot E, Gonzalez VE, Chen F, Finklestein J, et al. Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Cancer Discov 2016; 6: 664-679.
7. Bailey SR, Vatsa S, Larson RC, Bouffard AA, Scarfò I, Kann MC. Blockade or deletion of IFN reduces macrophage activation without compromising CAR T-cell function in hematologic malignancies. Blood Cancer Discovery 2022; 3: 136-153.
8. Manni S, Del Bufalo F, Merli P, Silvestris DA, Guercio M, Caruso S. Neutralizing IFN improves safety without compromising efficacy of CAR-T cell therapy in B-malignancies. Nat Commun 2023; 14: 423.
9. McNerney KO, DiNafia AM, Teachey DT, Grupp SA, Maude SL. Potential role of IFN- inhibition in refractory cytokine release syndrome with CART cell therapy. Blood Cancer Discover 2022; 3: 90-94.
10. Boulch M, Cazaux M, Cuffel A, Ruggiu M, Allain V, Corre B. A major role for CD4+ T cells in driving cytokine release syndrome during CAR T cell therapy. Cell Rep Med 2023; 4: 101161.
11. Liu Y, Fang Y, Chen X, Wang Z, Liang X, Zhang T. Gasdermin E-mediated target cell pyroptosis by CAR T cells triggers cytokine release syndrome. Sci Immunol 2020; 5: eaax7969.
12. Jiang M, Qi L, Li L, Li Y. The caspase-3/GSMDE signal pathway as a switch beteen apoptosis and pyroptosis in cancer. Cancer Death Discov 2020; 6: 112.
13. Hong F, Shi M, Cao J, Wang Y, Gong Y, Gao H, Li Z, Zheng J, Zang L.,He A, et al. Predictive role of endothelial activation in cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukemia. J Cell Mol Med 2021; 25: 11063-11074.
14. Hay KA, Hanafi LA, Li D, Gust J, Llies C, Wufel M, Lopez JA, Chen J, Chung D, Harju-Baker S, et al. Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy. Blood 2017; 130: 2295-2306.
15. Galli E, Sorà F, Hohaus S, Fresa A, Pansini I, Autore F. Endothelial activation predicts disseminated intravascular coagulopathy cytokine release syndrome and prognosis in patients treated with anti-CD19 CAR-T cells. Br J Haematol 2023; 201: 86-94.
16. Greenbaum U, Strati P, Saliba RM, Torres J, Rondon G, Nieto Y, Hosing C, Srour SA, Westin J, Fayad LE, et al. CRP and ferritin in addition to EASIX predict CAR-T related toxicity. Blood Adv 2021; 5: 2799-2806.
17. Singh N, Hofmann TJ, Gershenson Z, Lebine BL, Grupp S, Teachey DT, Barrett DM. Monocyte lineage derived IL-6 does not affect chimeric antigen receptor T-cell function. Cytotherapy 2017; 19: 867-880.
18. Hayden PJ, Roddie C, Bader P, Basak GW, Bonig H, Bonini C, Chabannon C, Ciceri F, Corbacioglu S, Ellard R, Sanchez-Guijo F, Jäger U, Hildebrandt M, Hudecek M, Kersten MJ, Köhl U, Kuball J, Mielke S, Mohty M, Murray J, Nagler A, Rees J, Rioufol C, Saccardi R, Snowden JA, Styczynski J, Subklewe M, Thieblemont C, Topp M, Ispizua ÁU, Chen D, Vrhovac R, Gribben JG, Kröger N, Einsele H, Yakoub-Agha I. Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA). Ann Oncol. 2022 Mar;33(3):259-275. doi: 10.1016/j.annonc.2021.12.003. Epub 2021 Dec 16. PMID: 34923107.
19. Xue L, Xu Q, Wang L, Yang X, Zhang Y, Hua X, Chai X, Yang Y, Chen Y, Tao, G.; et al. Chimeric antigen receptor T cells self-neutralizing IL6 storm in patients with hematologic malignancy. Cell Discov 2021; 7:84.
20. Kang L, Ma J, Lou X, Tang X, Xue S, Chen S, Qiu H, Miao M, Han Y, Wang Y, et al. Efficacy and safety of interleukin-6 -knockdown CD19-targeted CART cells (ssCART-19) for relapsed/refractory B-ALL. Blood 2023; 142 (suppl.1): 704.
21. Li X, Gong N, Tian F, Zhang S, Zhang Y, Wang Y, Qing G, Wang Y, Li F, Xu Y, et al. Suppression of cytokine release syndrome during CAR-T cell therapy via a subcutaneously injected interleukin-6-adsorbing hydrogel. Nat Biomed Engin 2023; 7: 1129-1141.
22. Sakamura RL, Roman CM, Harvei P, Siegler EL, Girsch JH, Sirpilla OL, Stewart CM, Yun K, Can I, Ogbodo OJ, et al. CD19 occupancy with Tafasitamab increases therapeutic index of CART19 cell therapy and diminishes severity of CRS. Blood 2024; 143: 258-271.
23. Santomasso BD, Nastoupil LJ, Adkins S, Lacchetti C, Schneider BJ, Anadkat M, Atkins MB, Brassil KJ, Caterino JM, Chau I, Davies MJ, Ernstoff MS, Fecher L, Funchain P, Jaiyesimi I, Mammen JS, Naidoo J, Naing A, Phillips T, Porter LD, Reichner CA, Seigel C, Song JM, Spira A, Suarez-Almazor M, Swami U, Thompson JA, Vikas P, Wang Y, Weber JS, Bollin K, Ghosh M. Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline. J Clin Oncol. 2021 Dec 10;39(35):3978-3992. doi: 10.1200/JCO.21.01992. Epub 2021 Nov 1. Erratum in: J Clin Oncol. 2022 Mar 10;40(8):919. doi: 10.1200/JCO.22.00279. PMID: 34724386.
24. Gust J, Ponce R, Liles C, garden GA, Turtle CJ, Cytokines in CART cell-associated neurotoxicity. Front Immunol 2020; 11: 577027.
25. Ferrari CJ, Bhutani M. Mechanisms and management of CART toxicity. Front Oncol 2024; 14: 1396490.
26. Gust J, Hay KA, Hanafi LA, Li D, Myerson D, Gonzalez-Cuyar LF, Yeung C, Liles WC, Wurfel M, Lopez JA, Chen J, et al. Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells. Cancer Discob 2017; 7: 1404-1419.
27. Santomasso BD, Park JH, Salloum D, Riviere I, Flynn J, Mead E, Helton E, Wang X, Senechal B, Purdon T, et al. Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia. Cancer Discov 2018; 8: 958-971.
28. Vinnekota JM, Biavasco F, Schwabenland M, Chhatbar C, Adams RC, Erny D, Duquesne S, El Khawansky NE, Schmidt D, et al. Targeting TFG-activated kinase-1 activation in microglia reduces CAR T immune effector cell-associated neurotoxicity syndrome. Nat Cancer 2024; 5: 1227-1249.
29. Storci G, De Felice F, Ricci F, Santi S, Masselodi D, Bertuccio SN, Laprovitera N, Dicataldo M, Rossini L, De Matteis S, et al. CAR+ extracellular vesicles predict ICANS in patients with B cell lymphomas treated with CD19-directed CAR-T cells. J Clin Invet 2024; 134: e173096.
30. Bachy E, LeGouill S, DiBlasi R, Sesques P, Manson G, Cartron G, Baeuvois D, Roulin L, Gros FX, Rubio MT, et al. A eral-world comparison of tisageleuclecel and axicabtagene ciloleucel CART cells in relapsed or refractory diffuse large B cell lymphoma. Nat Med 2022; 28: 2145-2154.
31. Liao CT, Zeng L, Lu S, Zheng S, Guo B, Ke Q, Wang M, Sun J, Rang C, He S, et al. Comparison of the efficacy and safety of axi-cel and tisa-cel based on meta-analysis. J Cancer 2024; 15: 5729-5741.
32. Van Oekelen O, Aleman A, Upadhyaya B, Schnakenburg S, Madduri D, Gavane S, Teruya-Feldstein J, Crary JF, Fowkes ME, Stacy CB, et al. Neurocognitive and hypokinetic movement disorder with features of parkinsonism following BCMA-targeting CAR-T cell therapy. Nat Med 2021; 27: 2099-2103.
33. Bardeja JG, Madduri D, Usmani SZ, Jakubowiak AJ, Agha M, Cohen AD. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet 2021; 398: 314-324.
34. Cohen AD, Parekh S, Santomasso B, Perez-Larraya JG, van de Donk N, Arnulf B, Mateos MV, Lendval N, Jackson CC, De Bragnasca K, et al. Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studes. Blood Cancer J 2022; 12: 32.
35. Karschnia P, Miller KC, Yee aj, Rejeski K, Connor Johnson C, Raje N, Frigault MJ, Dietrich J. Neurologic toxicities following adoptive immunotherapy with BCMA-directed CAR T cells. Blood 2023; 142: 1243-1247.
36. Gudera JA, Baehring JM, Karschnia P. Parkinsonism following chimeric antigen receptor T-cell therapy. JAMA Neurol doi:10.1001/jamaneurol.2024.2506.
37. Graham CE, Lee WH, Wiggin HR, Supper VM, Leick MB, Birocchi F, Yee AJ, Petrichenko A, Everett J, Bushman FD, et al. Chemotherapy-induced reversal of ciltacabtagene autoleucel-associated movement and neurocognitive toxicity. Blood 2023; 142: 1248-1252.
38. Marella M, Yao X, Carreira V, Bustamante M,Clark B, Jackson C, Zudaire E, Schecter J, Glover T, Shenton J, et al. Comprehensive BCMA expression profiling in adult normal human brain suggests a low risk of on-target neurotoxicity in BCMA-taregting multiple myeloma therapy. J Histochem Cytochem 2022 70. 273-287.
39. Hines MR, Knight TE, McNerney KO, Leick MB, Jain T, Ahmed S, Frigault MJ, Hill JA, Jain MD, Johnson WT, et al. Immune effector cell-associated hemphagocytic lymphohitiocytosis-like syndrome. Transplant Cell Ther 2023; 29: 438.e1-438.e.16.
40. Sandler RD, Tattersall RS, Schoemans H, Greco R, Badoglio M, Labopin M, Alexander T, Kirgirou K, Rovira M, Saif M, et al. Diagnosis and management of secondary HLH/MAS following HSCT and CAR-T cell therapy in adults; a review of the literature and a survey of practice within EMBT centres on behalf of the autoimmune diseases working party (TCWP). Front Immunol 2020; 11: 524.
41. Hines MR, Knight TE, McNerney KO, Leick MB, Jain T, Ahmed S, Frigault MJ, Hill JA, Jain MD, Johnson WT, Lin Y, Mahadeo KM, Maron GM, Marsh RA, Neelapu SS, Nikiforow S, Ombrello AK, Shah NN, Talleur AC, Turicek D, Vatsayan A, Wong SW, Maus MV, Komanduri KV, Berliner N, Henter JI, Perales MA, Frey NV, Teachey DT, Frank MJ, Shah NN. Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome. Transplant Cell Ther. 2023 Jul;29(7):438.e1-438.e16. doi: 10.1016/j.jtct.2023.03.006. Epub 2023 Mar 9. PMID: 36906275; PMCID: PMC10330221.
42. Lichtenstein DA, Schischilk F, SAteinber SM, Yates B, Wang HW, Inglefield J, Dulan-Florea A, Ceppi F, Hermida LC, et al. Characterization of HLH-like manifestations of a variant in patients receiving CD22 CAR-T cells. Blood 2021; 138: 2469-2484.
43. Rocco JM, Inglefield J, Yates B, Lichtenstein DA, Wang Y, Goffin L; Filipovic D, Schiffrin EJ, Shah NN. Free interleukin-18 is elevated in CD22 CAR T-cell-associated hemophagocytic-like toxicities. Blood Adv 2023; 7: 6134-6139.
44. Schultz LM, Jeyakumar N, Kramer AM, Sahaf B, Sianagesh H, Shiraz P, Agarwal N, Hamilton M, Erickson C, Jacobs A, et al. CD22 CART cells demonstrate high response rates and safety in pediatric and adult B-ALL: phase 1b results. Leukemia 2024; 38: 963-968.
45. Fauter M, Mainbourg S, Jammal TE, Guerber A, Zaepfel S, Henry T, Gerfaud-Valentin M, Sève P, Jamilloux Y. Extreme hyperferritinemia: causes and prognosis. J Clin Med 2022; 11, 5438.
46. Bami S, Vagrecha A, Soberman D, Badawi M, Cannone D, Lipton JM, Cross R, Levy CF. The use of anakinra in the treatment of secondary hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 2020; 67: e28581.
47. FDA Investigation serious risk of T-cell malignancy following BCMA-directed autologous chimeric antigen receptor (CAR) T cell immunotherapies. US Food & Drug administration. Available online: https://www.fda.gov/vaccines-bloof-biologics/safety-availability-biologics/fda-investigating-serios-risk-t-cell-malignancy-following-bcma-directed-orr-cd19-directed-autologous.
48. Verdun N, Marks P. Secondary cancers after chimeric antigen receptor T-cell therapy. N Engl J Med 2024; 390: 584-586.
49. Levine BL, Pasquini MC, Connolly JE, Ported DL, Gustafson MP, Boelens EM, Grupp SA, Maus MV, Locke FL, et al. unanswered questions following reports of secondary malignancies after CAR-T cell therapy. Nat Med 2024; 30: 338-341.
50. Elsallab M, Ellithi M, Lunning MA, D’Angelo C, Ma J, Perales MA, Frigault M, Maus MV. Second primary malignancies afetr commercial CAR T cell tehrapy: analysis of FDA adverse events reporting system (FAERS). Blood 2024; 143: 2099-2105.
51. Shen J; Hu R, Lin A, Jiang A, Tang B, Liu Z, Cheng Q, Miao K, Zhang J, Luo P. Characterization of second primary malignancies post CAR T-cell therapy: rael-world insights from the two global pharmacovigilance databases of FAERS and Vigibase. Lancet 2024; 73: 102684.
52. Tix T, Alhoumoud M, Shouval R, Scheffer Cliff ER, Perales MA, Dordas dos Santos D, Rejeski K. Second primary nalignancies after CAR T-cell therapy: a systematic review and meta-analysis of 5,517 lymphomas and myeloma patients. Clin Cancer Res 2024; 30: 4690-4700.
53. Ghilardi G, Fraietta JA, Gerson JN, Van Deerlin VM, Morrissette J, Caponetti JC, Paruzzo L, Harris JC, Chong EA, Susanibar Adaniya SP, et al. et al. T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy. Nat Med 2024; 30: 984-989.
54. Hamilton MP, Sugio T, Noordenbos T, Shi S, Bulterys P, Liu CL, Kang X, Olsen MN, Good Z, Dahiya S, et al. Risk of second malignancies and T-cell lymphoma after chimeric antigen receptor T-cell therapy. N Egnl J Med 2024; 390: 2047-2060.
55. Chihara D, Dore GM, Flowers CR, Morton LM. The bidirectional increased risk of B-cell lymphoma and T-cell lymphoma. Blood 2021; 139: 785-789.
56. Goel H, Rahul E, Gupta I, Chopra A, Ranjan A, Gupta AK, Prasad Meene J, Viswanathan GK, Bakhshi S, Misra A, et al. Molecular and genomic landscapes in secondary & therapy related acute myeloid leukemia. Am J Blood Res 2021; 11: 472-497.
57. Demoor-Goldschmidt C, de Vathaire F. Review of risk factors of secondary cancers among cancer survivors. Br J Radiol 2019; 92: 20180390.
58. Palumbo A, Bringhen S, Kumar SK, Lupparelli G, Usmani S, Waage S, Larocca A, van der Holt B, Musto P, Offidani M, et al. Second primary malignancies with lenalidomide therapy malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data. Lancet Oncol 2014; 15: 333-342.
59. Musto P, Anderson KC, Attal M, Richardon PG, Badros A, Hou J, Comenzo R, Du J, Durie BGM, San Miguerl J, et al. Second primary malignancies in multiple myeloma: an overview and IMWG consensus. Ann Oncol 2017; 28: 228-245.
60. Galli E, Rossi M, Pansini I, Viscovo M, Malara T, Colangelo M, Alma E, Valentini CG, Teofili L, Hohaus S, Sica S, Sorà F, Chiusolo P. Predicting therapy-related myeloid neoplasms after CAR-T with the Clonal Haematopoiesis Risk Score (CHRS). Br J Haematol. 2025 Jan;206(1):372-374. doi: 10.1111/bjh.19905. Epub 2024 Nov 13. PMID: 39539012.
61. Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Battencourt H, Bader P, Verneris MR, Stefanski HE, Myers GD, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med 2018; 378: 439-448.
62. Laetsch TW, Maude SL, Rives S, Hiramatsu H, Bittencourt H, Bader P, Baruchel A, Boyer M, De Moerloose B, Qayed M, et al. Three year update of Tisagenlecleucel in pediatric and young adult patients with relapsed/refractory acute lymphoblastic leukemia in the ELIANA trial. J Clin Oncol 2022; 41: 1664-1669.
63. Baird JH, Epstein DJ, Tamaresis JS, Ehlinger Z, Spiegel JY, Craig J. Immune reconstitution and infection complications following axicabtagene ciloleucel tehrapy for large B-cell lymphoma. Blood Adv 2021; 5: 143-155.
64. Sutherland NM, Zhou B, Zhang L. On M.S. Hong J.S, Pak A, Liu K.J, Frigault M.J, Maus M.V, Hill J.A, et al. Association of CD19+-targeted chimeric antigen receptor (CAR) T-cell therapy with hypogammaglobulinemia, infection and mortality. J Alelrg Cel Immunol 2024; in press.
65. Malenhorst JJ, Chen GM, Wang M, Porter DL, Chen C, Collins MA, Gao P, Bandyopadhyay S, Sun H, Zhao Z, Lundh S, et al. Decade-long leukemia remissions with persistence of CD4+ CAR T cells. Nature 2022; 602: 503-509.
66. Johnson G, Patel K, Arciola B, Perez AP, Wood A, Ionescu F, Logue JM, Albanyan O, Yasin H, Bachmeier CA, et al. Poor hematopoiesis reserve at the time of CD19 CAR T-cell infusion is associated with long-term B-cell aplasia. Blood 2023; 142 (suppl.1): 3512.
67. Kampouri E, Little JS, Rejeski K, Manuel O, Hammond SP, Hill JA. Infections after chimeric antigen receptor (CAR) T-cell therapy for hematologic malignancies. Transpl Infect Dis 2024; 25(suppl.1): e14157.
68. Rejeski K, Subklewe M, Aljurf M, Bachy E, Balduzzi A, Barbal P. Immune effector cell-associated hematotoxicity EHA/EBMT consensus grading and best practice recommendations. Blood 2023; 142: 865-877.
69. Yang Y, Peng H, Wang J, Li F. New insights into CART-cell hematological toxicities: manifestations, mechanisms, and effective management strategies. Exp Hematol Oncol 2024; 13: 110.
70. Rejesky K, Perez A, Sesques P, Hoster E, Bergi C, Jentzch L. CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed/refractory large B-cell lymphoma. Blood 2021; 138: 2499-2513.
71. Nair MS, Silbert SK, Rejeski K, Wilson KA, Lamble AJ, Valtis YK, Yates B, Arana AM, Shouval R, Curran KJ, et al. Development of ALL-Hematotox (ALL-HT): predicting post CAR T-cell hematotoxicity in B-cell acute lymphoblastic leukemia. Blood 2024; in press.
72. Strati P, Li X, Deng Q, Marques-Piubelli M, Henderson J, Watson G, Deaton L, Cain T, Yang H, Ravanmehr V, Fayad L, et al. Prolonged cytopenia following CD19 CAR T cell therapy is linked with bone marrow infiltration of clonally expanded IFN-expressing CD8 T cells. Cell Rep Med 2023; 4, 101158.
73. Drillet G, Lhomme F, De Guibert S, Manson G, Houot R. Prolonged thrombocytopenia after CAR T-cell therapy: the role of thrombopoietin receptor agonnistst. Blood Adv 2022; 7: 537-540.
74. Liévin R, Di Blasi R, Morin F, Galli E, Allain V, De Jorna R, Vercellino L, Parquet N, Mebarki M, Larghero J, de Kerviler E, Madelaine I, Caillat-Zucman S, Chevret S, Thieblemont C. Effect of early granulocyte-colony-stimulating factor administration in the prevention of febrile neutropenia and impact on toxicity and efficacy of anti-CD19 CAR-T in patients with relapsed/refractory B-cell lymphoma. Bone Marrow Transplant. 2022 Mar;57(3):431-439. doi: 10.1038/s41409-021-01526-0. Epub 2022 Jan 30. PMID: 35094012; PMCID: PMC8907072.
75. Rejeski K, Subklewe M, Aljurf M, Bachy E, Balduzzi A, Barba P, Bruno B, Benjamin R, Carrabba MG, Chabannon C, Ciceri F, Corradini P, Delgado J, Di Blasi R, Greco R, Houot R, Iacoboni G, Jäger U, Kersten MJ, Mielke S, Nagler A, Onida F, Peric Z, Roddie C, Ruggeri A, Sánchez-Guijo F, Sánchez-Ortega I, Schneidawind D, Schubert ML, Snowden JA, Thieblemont C, Topp M, Zinzani PL, Gribben JG, Bonini C, Sureda A, Yakoub-Agha I. Immune effector cell-associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations. Blood. 2023 Sep 7;142(10):865-877. doi: 10.1182/blood.2023020578. PMID: 37300386.
76. Roddie C, Dias J, O’Reilly MA, Abassian M, Cadinanos-Garai A, Vispute K, Bosshard-Carter L, Mitsikakou M, Mehra V, Roddy H, et al. Durable responses and low toxicity after off-rate CD19 chimeric antigen receptor-T therapy in adults with relapsed or refractory B-cell acute lymphoblastic leukemia. J Clin Oncol 2021; 39: 3352-3363.
77. Jabbour E, Tholouli E, Sandhu K, Shaughnessy P, Barba P, Guerriero M, Yallop D, Logan A, Abedi M, Sirieix PL, et al. Obecabtagene autoleucel (oce-cel, AUTO1) in adults with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL): overall survival (OS), event-free survival (EFS) and the potential impact of chimeric antigen receptor (CAR)-T cell persistency and consolidative stem cell transplantation (SCT) in the open-label, single-arm FELIX phase Ib/II study. J Clin Oncol 2024; 42(suppl.16): 6504.
78. Brudno JN, Lam N, Vanasse D, Shen Y, Rose JJ, Rossi J, Xue A, Bot A, Scholler N, Mikkilineni L, et al. Safety and feasibility of anti-CD19 CART cells with fully human binding domains in patients with B-cell lymphoma. Nat Med 2020; 26: 270-280.
79. Weinkove R, George P, Fyfe R, Dasyam N, Nouri Y, Ostapowicz T, Mullins S, Mester B, Giunti G, Bollard CM, et al. A phase I dose escalation trial at third-generation CD19-directed CAR T-cells incorporating CD28 and Toll-like receptor 2 (TLR2) intracellular domains for relapsed or refractory B-cell non-Hoggkin lymphomas (ENABLE). Blood 2023; 142(suppl.1): 890.
80. Park JH, Palomba ML, Devlin SM, Valtis YK, Sikder D, Senechal B, Wang X, Cathchart E, Liotta K, Yu A, et al. A phase I study of CD19-targeted 19(T2)28z1xx CAR T cells in adult patients with relapsed or refractory large B-cell lymphoma. Blood 2023; 142(suppl.1): 892-893.
81. Xue L, Yi Y, Xu Q, Wang L, Yang X, Zhang Y, Hua X, Chai X, Yang J, Chen Y, et al. Chimeric antigen receptor T cells self-neutralizing IL6 storm in patients with hematologic malignancy. Cell Discov 2021; 7: 84.
82. Hu B, Yi Y, Wang X, Xue L, Tao G. A potential best-in-class BCMA-CD19 bispecific CART with advanced safety by self-inhibiting IFNG signaling during CRS. J Clin Oncol 2014; 42 (suppl.16): 2502.
83. Yoshikawa T, Ito Y, Wu Z, Kasuya H, Nakashima T, Okamoto S, Amaishi Y, Zhang H, Li Y, Matsukawa T, et al. Development of a chimeric cytokione receptor that captures IL-6 and enhances the antitumoir response of CAR-T cells. Cell Rep Med 2024; 5: 101526.
84. Lin MY, Nam E, Shih RM, Shafer A, Bouren A, Ceja MA, Harris C, Chericha M, Vo KH, Kim M, et al. Self-regulating CAR-T cells modulates cytokine release syndrome in adoptive T-cell therapy. J Exp Med 2024; 221: in press.
85. Aldoss I, Khaled SK, Wang X, Palmer J, Wang Y, Wagner JR, Clark MC, Simpson J, Paul J, Vyas V, Chien SH, et al. Favorable activity and safety profile of memory-enriched CD19-targeted chimeric antigen receptor T-cell therapy in adults with high-risk relapse/refractory ALL. Clin Cancer Res 2023; 29: 742-753.
1. Cordas dos Santos, D.; Tix, T.; Shouval, R.; Gafter-Gvili, A.; Alberge, J.B.; Scheffer Cliff, E.; Theurich, S.; Bargwelt-Baildon, M.; Ghobrial, I.M.; Subklewe, M.; et al. A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy. Nat Med 2024; 30: 2667-2678.
2. Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, Maus MV, Park JH, Mead E, Pavletic S, Go WY, Eldjerou L, Gardner RA, Frey N, Curran KJ, Peggs K, Pasquini M, DiPersio JF, van den Brink MRM, Komanduri KV, Grupp SA, Neelapu SS. ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. Biol Blood Marrow Transplant. 2019 Apr;25(4):625-638. doi: 10.1016/j.bbmt.2018.12.758. Epub 2018 Dec 25. PMID: 30592986.
3. Morris EC, Neelapu SS, Giavridis T, Sadelain M. Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy. Nat Rev Immunol 2022; 22: 85-96.
4. Giavridis T, van der Stegen SJG, Eyquem J, Hamieh M, Piersigilli A, Sadelain M.CAR T cell-induced cytokine release syndrome is mediated by macrophages and ablated by IL-1 blockade. Nat Med 2018; 24: 731-738.
5. Norelli M, Camisa B, Barbiera G, Falcone l, Purevdorj A, Genua M, Sanvito F, Ponzoni M, Doglioni C, Cristofori P. Monocyte derived IL-1 and IL-6 are differentially required for cytokine release syndrome and neurotoxicity due to CAR-T cells. Nat Med 2018; 24: 739-748.
6. Teachey DT, Lacey SF, Shaw PA, Malenhorst JJ, Maude SL, Frey N, Pequinot E, Gonzalez VE, Chen F, Finklestein J, et al. Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Cancer Discov 2016; 6: 664-679.
7. Bailey SR, Vatsa S, Larson RC, Bouffard AA, Scarfò I, Kann MC. Blockade or deletion of IFN reduces macrophage activation without compromising CAR T-cell function in hematologic malignancies. Blood Cancer Discovery 2022; 3: 136-153.
8. Manni S, Del Bufalo F, Merli P, Silvestris DA, Guercio M, Caruso S. Neutralizing IFN improves safety without compromising efficacy of CAR-T cell therapy in B-malignancies. Nat Commun 2023; 14: 423.
9. McNerney KO, DiNafia AM, Teachey DT, Grupp SA, Maude SL. Potential role of IFN- inhibition in refractory cytokine release syndrome with CART cell therapy. Blood Cancer Discover 2022; 3: 90-94.
10. Boulch M, Cazaux M, Cuffel A, Ruggiu M, Allain V, Corre B. A major role for CD4+ T cells in driving cytokine release syndrome during CAR T cell therapy. Cell Rep Med 2023; 4: 101161.
11. Liu Y, Fang Y, Chen X, Wang Z, Liang X, Zhang T. Gasdermin E-mediated target cell pyroptosis by CAR T cells triggers cytokine release syndrome. Sci Immunol 2020; 5: eaax7969.
12. Jiang M, Qi L, Li L, Li Y. The caspase-3/GSMDE signal pathway as a switch beteen apoptosis and pyroptosis in cancer. Cancer Death Discov 2020; 6: 112.
13. Hong F, Shi M, Cao J, Wang Y, Gong Y, Gao H, Li Z, Zheng J, Zang L.,He A, et al. Predictive role of endothelial activation in cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukemia. J Cell Mol Med 2021; 25: 11063-11074.
14. Hay KA, Hanafi LA, Li D, Gust J, Llies C, Wufel M, Lopez JA, Chen J, Chung D, Harju-Baker S, et al. Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy. Blood 2017; 130: 2295-2306.
15. Galli E, Sorà F, Hohaus S, Fresa A, Pansini I, Autore F. Endothelial activation predicts disseminated intravascular coagulopathy cytokine release syndrome and prognosis in patients treated with anti-CD19 CAR-T cells. Br J Haematol 2023; 201: 86-94.
16. Greenbaum U, Strati P, Saliba RM, Torres J, Rondon G, Nieto Y, Hosing C, Srour SA, Westin J, Fayad LE, et al. CRP and ferritin in addition to EASIX predict CAR-T related toxicity. Blood Adv 2021; 5: 2799-2806.
17. Singh N, Hofmann TJ, Gershenson Z, Lebine BL, Grupp S, Teachey DT, Barrett DM. Monocyte lineage derived IL-6 does not affect chimeric antigen receptor T-cell function. Cytotherapy 2017; 19: 867-880.
18. Hayden PJ, Roddie C, Bader P, Basak GW, Bonig H, Bonini C, Chabannon C, Ciceri F, Corbacioglu S, Ellard R, Sanchez-Guijo F, Jäger U, Hildebrandt M, Hudecek M, Kersten MJ, Köhl U, Kuball J, Mielke S, Mohty M, Murray J, Nagler A, Rees J, Rioufol C, Saccardi R, Snowden JA, Styczynski J, Subklewe M, Thieblemont C, Topp M, Ispizua ÁU, Chen D, Vrhovac R, Gribben JG, Kröger N, Einsele H, Yakoub-Agha I. Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA). Ann Oncol. 2022 Mar;33(3):259-275. doi: 10.1016/j.annonc.2021.12.003. Epub 2021 Dec 16. PMID: 34923107.
19. Xue L, Xu Q, Wang L, Yang X, Zhang Y, Hua X, Chai X, Yang Y, Chen Y, Tao, G.; et al. Chimeric antigen receptor T cells self-neutralizing IL6 storm in patients with hematologic malignancy. Cell Discov 2021; 7:84.
20. Kang L, Ma J, Lou X, Tang X, Xue S, Chen S, Qiu H, Miao M, Han Y, Wang Y, et al. Efficacy and safety of interleukin-6 -knockdown CD19-targeted CART cells (ssCART-19) for relapsed/refractory B-ALL. Blood 2023; 142 (suppl.1): 704.
21. Li X, Gong N, Tian F, Zhang S, Zhang Y, Wang Y, Qing G, Wang Y, Li F, Xu Y, et al. Suppression of cytokine release syndrome during CAR-T cell therapy via a subcutaneously injected interleukin-6-adsorbing hydrogel. Nat Biomed Engin 2023; 7: 1129-1141.
22. Sakamura RL, Roman CM, Harvei P, Siegler EL, Girsch JH, Sirpilla OL, Stewart CM, Yun K, Can I, Ogbodo OJ, et al. CD19 occupancy with Tafasitamab increases therapeutic index of CART19 cell therapy and diminishes severity of CRS. Blood 2024; 143: 258-271.
23. Santomasso BD, Nastoupil LJ, Adkins S, Lacchetti C, Schneider BJ, Anadkat M, Atkins MB, Brassil KJ, Caterino JM, Chau I, Davies MJ, Ernstoff MS, Fecher L, Funchain P, Jaiyesimi I, Mammen JS, Naidoo J, Naing A, Phillips T, Porter LD, Reichner CA, Seigel C, Song JM, Spira A, Suarez-Almazor M, Swami U, Thompson JA, Vikas P, Wang Y, Weber JS, Bollin K, Ghosh M. Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline. J Clin Oncol. 2021 Dec 10;39(35):3978-3992. doi: 10.1200/JCO.21.01992. Epub 2021 Nov 1. Erratum in: J Clin Oncol. 2022 Mar 10;40(8):919. doi: 10.1200/JCO.22.00279. PMID: 34724386.
24. Gust J, Ponce R, Liles C, garden GA, Turtle CJ, Cytokines in CART cell-associated neurotoxicity. Front Immunol 2020; 11: 577027.
25. Ferrari CJ, Bhutani M. Mechanisms and management of CART toxicity. Front Oncol 2024; 14: 1396490.
26. Gust J, Hay KA, Hanafi LA, Li D, Myerson D, Gonzalez-Cuyar LF, Yeung C, Liles WC, Wurfel M, Lopez JA, Chen J, et al. Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells. Cancer Discob 2017; 7: 1404-1419.
27. Santomasso BD, Park JH, Salloum D, Riviere I, Flynn J, Mead E, Helton E, Wang X, Senechal B, Purdon T, et al. Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia. Cancer Discov 2018; 8: 958-971.
28. Vinnekota JM, Biavasco F, Schwabenland M, Chhatbar C, Adams RC, Erny D, Duquesne S, El Khawansky NE, Schmidt D, et al. Targeting TFG-activated kinase-1 activation in microglia reduces CAR T immune effector cell-associated neurotoxicity syndrome. Nat Cancer 2024; 5: 1227-1249.
29. Storci G, De Felice F, Ricci F, Santi S, Masselodi D, Bertuccio SN, Laprovitera N, Dicataldo M, Rossini L, De Matteis S, et al. CAR+ extracellular vesicles predict ICANS in patients with B cell lymphomas treated with CD19-directed CAR-T cells. J Clin Invet 2024; 134: e173096.
30. Bachy E, LeGouill S, DiBlasi R, Sesques P, Manson G, Cartron G, Baeuvois D, Roulin L, Gros FX, Rubio MT, et al. A eral-world comparison of tisageleuclecel and axicabtagene ciloleucel CART cells in relapsed or refractory diffuse large B cell lymphoma. Nat Med 2022; 28: 2145-2154.
31. Liao CT, Zeng L, Lu S, Zheng S, Guo B, Ke Q, Wang M, Sun J, Rang C, He S, et al. Comparison of the efficacy and safety of axi-cel and tisa-cel based on meta-analysis. J Cancer 2024; 15: 5729-5741.
32. Van Oekelen O, Aleman A, Upadhyaya B, Schnakenburg S, Madduri D, Gavane S, Teruya-Feldstein J, Crary JF, Fowkes ME, Stacy CB, et al. Neurocognitive and hypokinetic movement disorder with features of parkinsonism following BCMA-targeting CAR-T cell therapy. Nat Med 2021; 27: 2099-2103.
33. Bardeja JG, Madduri D, Usmani SZ, Jakubowiak AJ, Agha M, Cohen AD. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet 2021; 398: 314-324.
34. Cohen AD, Parekh S, Santomasso B, Perez-Larraya JG, van de Donk N, Arnulf B, Mateos MV, Lendval N, Jackson CC, De Bragnasca K, et al. Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studes. Blood Cancer J 2022; 12: 32.
35. Karschnia P, Miller KC, Yee aj, Rejeski K, Connor Johnson C, Raje N, Frigault MJ, Dietrich J. Neurologic toxicities following adoptive immunotherapy with BCMA-directed CAR T cells. Blood 2023; 142: 1243-1247.
36. Gudera JA, Baehring JM, Karschnia P. Parkinsonism following chimeric antigen receptor T-cell therapy. JAMA Neurol doi:10.1001/jamaneurol.2024.2506.
37. Graham CE, Lee WH, Wiggin HR, Supper VM, Leick MB, Birocchi F, Yee AJ, Petrichenko A, Everett J, Bushman FD, et al. Chemotherapy-induced reversal of ciltacabtagene autoleucel-associated movement and neurocognitive toxicity. Blood 2023; 142: 1248-1252.
38. Marella M, Yao X, Carreira V, Bustamante M,Clark B, Jackson C, Zudaire E, Schecter J, Glover T, Shenton J, et al. Comprehensive BCMA expression profiling in adult normal human brain suggests a low risk of on-target neurotoxicity in BCMA-taregting multiple myeloma therapy. J Histochem Cytochem 2022 70. 273-287.
39. Hines MR, Knight TE, McNerney KO, Leick MB, Jain T, Ahmed S, Frigault MJ, Hill JA, Jain MD, Johnson WT, et al. Immune effector cell-associated hemphagocytic lymphohitiocytosis-like syndrome. Transplant Cell Ther 2023; 29: 438.e1-438.e.16.
40. Sandler RD, Tattersall RS, Schoemans H, Greco R, Badoglio M, Labopin M, Alexander T, Kirgirou K, Rovira M, Saif M, et al. Diagnosis and management of secondary HLH/MAS following HSCT and CAR-T cell therapy in adults; a review of the literature and a survey of practice within EMBT centres on behalf of the autoimmune diseases working party (TCWP). Front Immunol 2020; 11: 524.
41. Hines MR, Knight TE, McNerney KO, Leick MB, Jain T, Ahmed S, Frigault MJ, Hill JA, Jain MD, Johnson WT, Lin Y, Mahadeo KM, Maron GM, Marsh RA, Neelapu SS, Nikiforow S, Ombrello AK, Shah NN, Talleur AC, Turicek D, Vatsayan A, Wong SW, Maus MV, Komanduri KV, Berliner N, Henter JI, Perales MA, Frey NV, Teachey DT, Frank MJ, Shah NN. Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome. Transplant Cell Ther. 2023 Jul;29(7):438.e1-438.e16. doi: 10.1016/j.jtct.2023.03.006. Epub 2023 Mar 9. PMID: 36906275; PMCID: PMC10330221.
42. Lichtenstein DA, Schischilk F, SAteinber SM, Yates B, Wang HW, Inglefield J, Dulan-Florea A, Ceppi F, Hermida LC, et al. Characterization of HLH-like manifestations of a variant in patients receiving CD22 CAR-T cells. Blood 2021; 138: 2469-2484.
43. Rocco JM, Inglefield J, Yates B, Lichtenstein DA, Wang Y, Goffin L; Filipovic D, Schiffrin EJ, Shah NN. Free interleukin-18 is elevated in CD22 CAR T-cell-associated hemophagocytic-like toxicities. Blood Adv 2023; 7: 6134-6139.
44. Schultz LM, Jeyakumar N, Kramer AM, Sahaf B, Sianagesh H, Shiraz P, Agarwal N, Hamilton M, Erickson C, Jacobs A, et al. CD22 CART cells demonstrate high response rates and safety in pediatric and adult B-ALL: phase 1b results. Leukemia 2024; 38: 963-968.
45. Fauter M, Mainbourg S, Jammal TE, Guerber A, Zaepfel S, Henry T, Gerfaud-Valentin M, Sève P, Jamilloux Y. Extreme hyperferritinemia: causes and prognosis. J Clin Med 2022; 11, 5438.
46. Bami S, Vagrecha A, Soberman D, Badawi M, Cannone D, Lipton JM, Cross R, Levy CF. The use of anakinra in the treatment of secondary hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 2020; 67: e28581.
47. FDA Investigation serious risk of T-cell malignancy following BCMA-directed autologous chimeric antigen receptor (CAR) T cell immunotherapies. US Food & Drug administration. Available online: https://www.fda.gov/vaccines-bloof-biologics/safety-availability-biologics/fda-investigating-serios-risk-t-cell-malignancy-following-bcma-directed-orr-cd19-directed-autologous.
48. Verdun N, Marks P. Secondary cancers after chimeric antigen receptor T-cell therapy. N Engl J Med 2024; 390: 584-586.
49. Levine BL, Pasquini MC, Connolly JE, Ported DL, Gustafson MP, Boelens EM, Grupp SA, Maus MV, Locke FL, et al. unanswered questions following reports of secondary malignancies after CAR-T cell therapy. Nat Med 2024; 30: 338-341.
50. Elsallab M, Ellithi M, Lunning MA, D’Angelo C, Ma J, Perales MA, Frigault M, Maus MV. Second primary malignancies afetr commercial CAR T cell tehrapy: analysis of FDA adverse events reporting system (FAERS). Blood 2024; 143: 2099-2105.
51. Shen J; Hu R, Lin A, Jiang A, Tang B, Liu Z, Cheng Q, Miao K, Zhang J, Luo P. Characterization of second primary malignancies post CAR T-cell therapy: rael-world insights from the two global pharmacovigilance databases of FAERS and Vigibase. Lancet 2024; 73: 102684.
52. Tix T, Alhoumoud M, Shouval R, Scheffer Cliff ER, Perales MA, Dordas dos Santos D, Rejeski K. Second primary nalignancies after CAR T-cell therapy: a systematic review and meta-analysis of 5,517 lymphomas and myeloma patients. Clin Cancer Res 2024; 30: 4690-4700.
53. Ghilardi G, Fraietta JA, Gerson JN, Van Deerlin VM, Morrissette J, Caponetti JC, Paruzzo L, Harris JC, Chong EA, Susanibar Adaniya SP, et al. et al. T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy. Nat Med 2024; 30: 984-989.
54. Hamilton MP, Sugio T, Noordenbos T, Shi S, Bulterys P, Liu CL, Kang X, Olsen MN, Good Z, Dahiya S, et al. Risk of second malignancies and T-cell lymphoma after chimeric antigen receptor T-cell therapy. N Egnl J Med 2024; 390: 2047-2060.
55. Chihara D, Dore GM, Flowers CR, Morton LM. The bidirectional increased risk of B-cell lymphoma and T-cell lymphoma. Blood 2021; 139: 785-789.
56. Goel H, Rahul E, Gupta I, Chopra A, Ranjan A, Gupta AK, Prasad Meene J, Viswanathan GK, Bakhshi S, Misra A, et al. Molecular and genomic landscapes in secondary & therapy related acute myeloid leukemia. Am J Blood Res 2021; 11: 472-497.
57. Demoor-Goldschmidt C, de Vathaire F. Review of risk factors of secondary cancers among cancer survivors. Br J Radiol 2019; 92: 20180390.
58. Palumbo A, Bringhen S, Kumar SK, Lupparelli G, Usmani S, Waage S, Larocca A, van der Holt B, Musto P, Offidani M, et al. Second primary malignancies with lenalidomide therapy malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data. Lancet Oncol 2014; 15: 333-342.
59. Musto P, Anderson KC, Attal M, Richardon PG, Badros A, Hou J, Comenzo R, Du J, Durie BGM, San Miguerl J, et al. Second primary malignancies in multiple myeloma: an overview and IMWG consensus. Ann Oncol 2017; 28: 228-245.
60. Galli E, Rossi M, Pansini I, Viscovo M, Malara T, Colangelo M, Alma E, Valentini CG, Teofili L, Hohaus S, Sica S, Sorà F, Chiusolo P. Predicting therapy-related myeloid neoplasms after CAR-T with the Clonal Haematopoiesis Risk Score (CHRS). Br J Haematol. 2025 Jan;206(1):372-374. doi: 10.1111/bjh.19905. Epub 2024 Nov 13. PMID: 39539012.
61. Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Battencourt H, Bader P, Verneris MR, Stefanski HE, Myers GD, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med 2018; 378: 439-448.
62. Laetsch TW, Maude SL, Rives S, Hiramatsu H, Bittencourt H, Bader P, Baruchel A, Boyer M, De Moerloose B, Qayed M, et al. Three year update of Tisagenlecleucel in pediatric and young adult patients with relapsed/refractory acute lymphoblastic leukemia in the ELIANA trial. J Clin Oncol 2022; 41: 1664-1669.
63. Baird JH, Epstein DJ, Tamaresis JS, Ehlinger Z, Spiegel JY, Craig J. Immune reconstitution and infection complications following axicabtagene ciloleucel tehrapy for large B-cell lymphoma. Blood Adv 2021; 5: 143-155.
64. Sutherland NM, Zhou B, Zhang L. On M.S. Hong J.S, Pak A, Liu K.J, Frigault M.J, Maus M.V, Hill J.A, et al. Association of CD19+-targeted chimeric antigen receptor (CAR) T-cell therapy with hypogammaglobulinemia, infection and mortality. J Alelrg Cel Immunol 2024; in press.
65. Malenhorst JJ, Chen GM, Wang M, Porter DL, Chen C, Collins MA, Gao P, Bandyopadhyay S, Sun H, Zhao Z, Lundh S, et al. Decade-long leukemia remissions with persistence of CD4+ CAR T cells. Nature 2022; 602: 503-509.
66. Johnson G, Patel K, Arciola B, Perez AP, Wood A, Ionescu F, Logue JM, Albanyan O, Yasin H, Bachmeier CA, et al. Poor hematopoiesis reserve at the time of CD19 CAR T-cell infusion is associated with long-term B-cell aplasia. Blood 2023; 142 (suppl.1): 3512.
67. Kampouri E, Little JS, Rejeski K, Manuel O, Hammond SP, Hill JA. Infections after chimeric antigen receptor (CAR) T-cell therapy for hematologic malignancies. Transpl Infect Dis 2024; 25(suppl.1): e14157.
68. Rejeski K, Subklewe M, Aljurf M, Bachy E, Balduzzi A, Barbal P. Immune effector cell-associated hematotoxicity EHA/EBMT consensus grading and best practice recommendations. Blood 2023; 142: 865-877.
69. Yang Y, Peng H, Wang J, Li F. New insights into CART-cell hematological toxicities: manifestations, mechanisms, and effective management strategies. Exp Hematol Oncol 2024; 13: 110.
70. Rejesky K, Perez A, Sesques P, Hoster E, Bergi C, Jentzch L. CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed/refractory large B-cell lymphoma. Blood 2021; 138: 2499-2513.
71. Nair MS, Silbert SK, Rejeski K, Wilson KA, Lamble AJ, Valtis YK, Yates B, Arana AM, Shouval R, Curran KJ, et al. Development of ALL-Hematotox (ALL-HT): predicting post CAR T-cell hematotoxicity in B-cell acute lymphoblastic leukemia. Blood 2024; in press.
72. Strati P, Li X, Deng Q, Marques-Piubelli M, Henderson J, Watson G, Deaton L, Cain T, Yang H, Ravanmehr V, Fayad L, et al. Prolonged cytopenia following CD19 CAR T cell therapy is linked with bone marrow infiltration of clonally expanded IFN-expressing CD8 T cells. Cell Rep Med 2023; 4, 101158.
73. Drillet G, Lhomme F, De Guibert S, Manson G, Houot R. Prolonged thrombocytopenia after CAR T-cell therapy: the role of thrombopoietin receptor agonnistst. Blood Adv 2022; 7: 537-540.
74. Liévin R, Di Blasi R, Morin F, Galli E, Allain V, De Jorna R, Vercellino L, Parquet N, Mebarki M, Larghero J, de Kerviler E, Madelaine I, Caillat-Zucman S, Chevret S, Thieblemont C. Effect of early granulocyte-colony-stimulating factor administration in the prevention of febrile neutropenia and impact on toxicity and efficacy of anti-CD19 CAR-T in patients with relapsed/refractory B-cell lymphoma. Bone Marrow Transplant. 2022 Mar;57(3):431-439. doi: 10.1038/s41409-021-01526-0. Epub 2022 Jan 30. PMID: 35094012; PMCID: PMC8907072.
75. Rejeski K, Subklewe M, Aljurf M, Bachy E, Balduzzi A, Barba P, Bruno B, Benjamin R, Carrabba MG, Chabannon C, Ciceri F, Corradini P, Delgado J, Di Blasi R, Greco R, Houot R, Iacoboni G, Jäger U, Kersten MJ, Mielke S, Nagler A, Onida F, Peric Z, Roddie C, Ruggeri A, Sánchez-Guijo F, Sánchez-Ortega I, Schneidawind D, Schubert ML, Snowden JA, Thieblemont C, Topp M, Zinzani PL, Gribben JG, Bonini C, Sureda A, Yakoub-Agha I. Immune effector cell-associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations. Blood. 2023 Sep 7;142(10):865-877. doi: 10.1182/blood.2023020578. PMID: 37300386.
76. Roddie C, Dias J, O’Reilly MA, Abassian M, Cadinanos-Garai A, Vispute K, Bosshard-Carter L, Mitsikakou M, Mehra V, Roddy H, et al. Durable responses and low toxicity after off-rate CD19 chimeric antigen receptor-T therapy in adults with relapsed or refractory B-cell acute lymphoblastic leukemia. J Clin Oncol 2021; 39: 3352-3363.
77. Jabbour E, Tholouli E, Sandhu K, Shaughnessy P, Barba P, Guerriero M, Yallop D, Logan A, Abedi M, Sirieix PL, et al. Obecabtagene autoleucel (oce-cel, AUTO1) in adults with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL): overall survival (OS), event-free survival (EFS) and the potential impact of chimeric antigen receptor (CAR)-T cell persistency and consolidative stem cell transplantation (SCT) in the open-label, single-arm FELIX phase Ib/II study. J Clin Oncol 2024; 42(suppl.16): 6504.
78. Brudno JN, Lam N, Vanasse D, Shen Y, Rose JJ, Rossi J, Xue A, Bot A, Scholler N, Mikkilineni L, et al. Safety and feasibility of anti-CD19 CART cells with fully human binding domains in patients with B-cell lymphoma. Nat Med 2020; 26: 270-280.
79. Weinkove R, George P, Fyfe R, Dasyam N, Nouri Y, Ostapowicz T, Mullins S, Mester B, Giunti G, Bollard CM, et al. A phase I dose escalation trial at third-generation CD19-directed CAR T-cells incorporating CD28 and Toll-like receptor 2 (TLR2) intracellular domains for relapsed or refractory B-cell non-Hoggkin lymphomas (ENABLE). Blood 2023; 142(suppl.1): 890.
80. Park JH, Palomba ML, Devlin SM, Valtis YK, Sikder D, Senechal B, Wang X, Cathchart E, Liotta K, Yu A, et al. A phase I study of CD19-targeted 19(T2)28z1xx CAR T cells in adult patients with relapsed or refractory large B-cell lymphoma. Blood 2023; 142(suppl.1): 892-893.
81. Xue L, Yi Y, Xu Q, Wang L, Yang X, Zhang Y, Hua X, Chai X, Yang J, Chen Y, et al. Chimeric antigen receptor T cells self-neutralizing IL6 storm in patients with hematologic malignancy. Cell Discov 2021; 7: 84.
82. Hu B, Yi Y, Wang X, Xue L, Tao G. A potential best-in-class BCMA-CD19 bispecific CART with advanced safety by self-inhibiting IFNG signaling during CRS. J Clin Oncol 2014; 42 (suppl.16): 2502.
83. Yoshikawa T, Ito Y, Wu Z, Kasuya H, Nakashima T, Okamoto S, Amaishi Y, Zhang H, Li Y, Matsukawa T, et al. Development of a chimeric cytokione receptor that captures IL-6 and enhances the antitumoir response of CAR-T cells. Cell Rep Med 2024; 5: 101526.
84. Lin MY, Nam E, Shih RM, Shafer A, Bouren A, Ceja MA, Harris C, Chericha M, Vo KH, Kim M, et al. Self-regulating CAR-T cells modulates cytokine release syndrome in adoptive T-cell therapy. J Exp Med 2024; 221: in press.
85. Aldoss I, Khaled SK, Wang X, Palmer J, Wang Y, Wagner JR, Clark MC, Simpson J, Paul J, Vyas V, Chien SH, et al. Favorable activity and safety profile of memory-enriched CD19-targeted chimeric antigen receptor T-cell therapy in adults with high-risk relapse/refractory ALL. Clin Cancer Res 2023; 29: 742-753.
Article Sidebar
Published
Apr 30, 2025
Article Details
How to Cite
Testa, U. (2025) “TOXICITIES ASSOCIATED WITH CAR-T CELL THERAPIES: CAR-T Cell Toxicity”, Mediterranean Journal of Hematology and Infectious Diseases, 17(1), p. e2025039. doi: 10.4084/MJHID.2025.039.
Section
Review Articles
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Transfer of Copyright and Permission to Reproduce Parts of Published Papers. Authors will grant copyright of their articles to the Institute of Hematology, Catholic University, Rome . No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.